Janssen to Assume CAELYX(R) Global Marketing Rights From Merck

BEERSE, Belgium, September 30, 2010 - Marketing rights for CAEYLX(R) (pegylated liposomal doxorubicin
hydrochloride) outside the United States will be transitioned from an
affiliate of Merck & Co., Inc. ("Merck") to Janssen Pharmaceutical Companies,
on December 31, 2010. Merck is known as MSD outside the United States and
Canada. CAELYX is a treatment for certain types of cancer.

(Logo: www.newscom.com/cgi-bin/prnh/20100924/409508 )

Currently, MSD, through an affiliate, holds rights to market the
medication under a distribution agreement with ALZA Corporation, an affiliate
of Janssen, which was executed in 1996. This distribution agreement with the
affiliate of MSD expires on December 31, 2010, and marketing rights will be
transferred back to ALZA Corporation. Janssen affiliates will assume
marketing and distribution responsibilities for the product beginning January
1, 2011.

Since the agreement was put in place, the affiliate of MSD has held
rights to CAELYX in Europe and associated countries, Canada, Latin America,
Middle East and Asia-Pacific (excluding Japan). Janssen affiliates market the
product in the United States, Japan and Israel, under the trade name
DOXIL(R). Combined, CAELYX and DOXIL are marketed in more than 80 countries.

"CAELYX will become our first global product for the treatment of solid
tumors. It represents an important addition to our growing portfolio and
growing global presence that reflects our ongoing commitment to delivering
important therapeutic options for patients with cancer," said Jim Baker,
Worldwide Vice President, Oncology and Supportive Care for Janssen. "Both
Janssen and MSD are committed to working together on a smooth transition and
ensuring an uninterrupted drug supply for patients."

No product name changes are planned in connection with the transition of
marketing rights.

CAELYX is a long-circulating pegylated liposomal formulation of
doxorubicin hydrochloride, a widely used cytotoxic agent. Therefore, CAELYX
should not be used interchangeably with other formulations of doxorubicin
hydrochloride.

CAELYX is approved in the European Union (EU) as monotherapy for
metastatic breast cancer in patients where there is an increased cardiac
risk. CAELYX is also approved in the EU for the treatment of advanced ovarian
cancer in women who have failed first-line, platinum-based therapy and for
the treatment of AIDS-related Kaposi's sarcoma in patients with low CD4
counts (<200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral
disease and in combination with VELCADE(R) (bortezomib) for the treatment of
progressive multiple myeloma in patients who have received at least one prior
therapy and who have already undergone or are unsuitable for bone marrow
transplant. Full prescribing information for CAELYX can be found at
www.ema.europa.eu/humandocs/Humans/EPAR/caelyx/caelyx.htm

About Janssen

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to
addressing and solving the most important unmet medical needs of our time,
including oncology (e.g. multiple myeloma and prostate cancer), immunology
(e.g. psoriasis),neuroscience (e.g. schizophrenia, dementia and pain),
infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and
cardiovascular and metabolic diseases (e.g. diabetes).

Driven by our commitment to patients, we develop sustainable, integrated
healthcare solutions by working side-by-side with healthcare stakeholders,
based on partnerships of trust and transparency.

More information can be found at www.janssen-emea.com

(This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Janssen, ALZA Corporation and/or Johnson &
Johnson's expectations and projections. Risks and uncertainties include
general industry conditions and competition; economic conditions, such as
interest rate and currency exchange rate fluctuations; technological advances
and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; domestic and foreign
health care reforms and governmental laws and regulations; and trends toward
health care cost containment. A further list and description of these risks,
uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended January 3,
2010. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Neither Janssen, ALZA Corporation or Johnson & Johnson undertake to
update any forward-looking statements as a result of new information or
future events or developments.)

    Media contact:

    Brigitte Byl
    Janssen, Public Affairs and Communications
    Europe, Middle East & Africa
    +32(0)14-60-71-72

    Investor Relations contacts:

    Stan Panasewicz,
    Johnson & Johnson Headquarters
    +1(0)732-524-2524

Media contact: Brigitte Byl, Janssen, Public Affairs and Communications, Europe, Middle East & Africa, +32(0)14-60-71-72; Investor Relations contacts: Stan Panasewicz, Johnson & Johnson Headquarters, +1(0)732-524-2524.